JP2012507535A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507535A5
JP2012507535A5 JP2011534624A JP2011534624A JP2012507535A5 JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5 JP 2011534624 A JP2011534624 A JP 2011534624A JP 2011534624 A JP2011534624 A JP 2011534624A JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
hydrogen
fluoro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061573 external-priority patent/WO2010062507A1/en
Publication of JP2012507535A publication Critical patent/JP2012507535A/ja
Publication of JP2012507535A5 publication Critical patent/JP2012507535A5/ja
Pending legal-status Critical Current

Links

JP2011534624A 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト Pending JP2012507535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
US61/110,703 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
JP2012507535A JP2012507535A (ja) 2012-03-29
JP2012507535A5 true JP2012507535A5 (enExample) 2012-12-13

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534624A Pending JP2012507535A (ja) 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (29)

Country Link
US (1) US8404687B2 (enExample)
EP (1) EP2364185B1 (enExample)
JP (1) JP2012507535A (enExample)
KR (1) KR101335746B1 (enExample)
CN (1) CN102202737B (enExample)
AU (1) AU2009320251C1 (enExample)
BR (1) BRPI0921437A2 (enExample)
CA (1) CA2742539C (enExample)
CL (1) CL2011000979A1 (enExample)
CO (1) CO6382123A2 (enExample)
CR (1) CR20110202A (enExample)
CY (1) CY1114023T1 (enExample)
DK (1) DK2364185T3 (enExample)
EA (1) EA018931B1 (enExample)
EC (1) ECSP11011021A (enExample)
ES (1) ES2418479T3 (enExample)
HR (1) HRP20130527T1 (enExample)
IL (1) IL211841A0 (enExample)
MA (1) MA32726B1 (enExample)
MX (1) MX2011004683A (enExample)
NZ (1) NZ591945A (enExample)
PE (1) PE20110433A1 (enExample)
PL (1) PL2364185T3 (enExample)
PT (1) PT2364185E (enExample)
SI (1) SI2364185T1 (enExample)
TN (1) TN2011000166A1 (enExample)
UA (1) UA102115C2 (enExample)
WO (1) WO2010062507A1 (enExample)
ZA (1) ZA201102448B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536168B2 (en) * 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
CN119907797A (zh) * 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012530705A5 (enExample)
JP2011529054A5 (enExample)
JP2010523692A5 (enExample)
JP2013537203A5 (enExample)
JP2014515013A5 (enExample)
JP2016503786A5 (enExample)
JP2011527666A5 (enExample)
JP2011519854A5 (enExample)
JP2011500550A5 (enExample)
JP2011528658A5 (enExample)
JP2009545527A5 (enExample)
JP2010513478A5 (enExample)
JP2010533722A5 (enExample)
JP2009515988A5 (enExample)
JP2017504611A5 (enExample)
JP2013523733A5 (enExample)
JP2009535462A5 (enExample)
JP2006526031A5 (enExample)
JP2011527332A5 (enExample)
JP2010521516A5 (enExample)
JP2015531774A5 (enExample)
JP2012509265A5 (enExample)
JP2008513510A5 (enExample)
JP2013544854A5 (enExample)
JP2014518212A5 (ja) 化合物及び組成物